Insight journal, Insight journal - Company

Seattle Genetics : Biotech industry partnering activity 2009-2014

Posted on 22 July 2014

Tags: , ,

Seattle Genetics, a successful big biotech industry headquartered in Seattle, focuses its effort on advancing antibody drug conjugate technology targeted toward cancer treatment. The company has a unique number of products in its pipeline and is always on the lookout for collaborators for strategic partnerships.

The following figure shows the numbers of Seattle Genetics partnering deal announcements since 2009.

Figure 1: Seattle Genetics partnering deals 2009-2014

1

 

 

 

 

 

 

Source: Current Agreements, 2014

Seattle Genetics works only with cancer as an indication, advancing antibody drug conjugates to fight the disease. The company finds companies to partner in the areas of lymphoma, solid tumors and leukemia.

The following table provides an overview of the partnering deals announced by Seattle Genetics based on oncology therapy area disclosed. Our report provides a more detailed insight into the precise therapeutic target of each deal. See report details : Partnering Deals and Alliances with Seattle Genetics

Figure 2: Seattle Genetics partnering deals by therapy area 2009-2014

2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Source: Current Agreements, 2014

Further analysis of these deals shows that Seattle Genetics has a preference for licensing deals and co-development deals similar to many other top pharmaceutical or big pharma companies. Seattle Genetics has collaborated with companies such as Takeda, Bayer, Agensys, Abbott, Millenium, Genmab, Oxford BioTherapeutics to co develop ADC’s for cancer.

The following table provides an overview of the partnering deals announced by Seattle Genetics based on deal type disclosed.

Figure 3: Seattle Genetics partnering deals by deal type 2009-2014

3

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Source: Current Agreements, 2014

When looking at stage of development at partnering deal signing, the most popular stage at signing is discovery stage with 9 deal announcements since 2009, closely followed by preclinical stage deals. Seattle Genetics has signed deals worth around $2.259 billion since 2009 with its highest valued deal with Bayer Healthcare for an ADC at discovery stage.

The following table provides an overview of the partnering deals announced by Seattle Genetics based on stage of development at signature.

Figure 4: Seattle Genetics partnering by stage of development 2009-2014

4

 

 

 

 

 

 

 

Source: Current Agreements, 2014

Seattle Genetics has signed over 20 partnering and licensing deals since 2009. The following provides two of the top deals by headline value signed by Seattle Genetics with the big pharma companies Bayer and Abbott for ADC technology.

Figure 5: Top Seattle Genetics partnering deals by headline value 2009-2014

5

 

 

 

 

 

 

 

 

 

Source: Current Agreements, 2014

Seattle Genetics has a number of unique products in its clinical trials pipeline and is always on the lookout for collaborations and advancements. The company with its shooting profits is looking to grow stronger in the future and hoping to etch its name in the top 10 biotechnology list in the world.

~ Shamini Thiagarajan

Seattle Genetics partnering at Current Agreements

View all partnering deals for Seattle Genetics: 2014 | 2013 | 2012 | 2011 | 2010 | 2009

Full details on each deal can be found at Current Agreements (subscription required)

 

More

Summary profile data for Seattle Genetics

Partnering interests for Seattle Genetics

No M&A activity for Seattle Genetics

 

Available reports from Current Partnering

Report: Partnering Deals and Alliances with Seattle Genetics

Report: Partnering Deals and Alliances with Big Biotech

 

Available resources for deal coverage for Seattle Genetics

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Read: more on Seattle Genetics company profile, recent partnering, M&A and financing news and articles

 

Related

Report: Licensing Terms and Agreements in Pharma, Biotech and Diagnostics

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk

View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk

Follow us on:LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

 

Print Friendly, PDF & Email

Leave a Reply

 

cpbannerad300x150new1gif
rauconbadgejpg
e78banner300x150animgif
cabannerad300x150new4gif
e79banner300x150gif
e78banner300x150animgif